The groundbreaking success of Sildenafil undeniably reshaped the pharmaceutical landscape, but betting in companies strongly reliant on unbranded versions presents a complex picture. Despite early returns were substantial, the cessation of patents and the appearance of cheaper alternatives have weakened market share. Therefore, a thorough analysis